- In October 2023, GEn1E Lifesciences Inc. announced that it had secured a contract from the United States Department of Health and Human Services, Biomedical Advanced Research and Development Authority (BARDA), to support the development of its novel therapy, GEn-1124, aimed at treating acute respiratory distress syndrome (ARDS)
- In April 2023, Direct Biologics announced that the U.S. FDA had approved the expansion of its pivotal Phase 3 EXTINGUISH ARDS trial to evaluate the safety and efficacy of ExoFlo for the treatment of moderate-to-severe ARDS caused by various underlying conditions
- In April 2022, the Food and Drug Administration (FDA) granted approval to Direct Biologics to proceed with a landmark Phase 3 clinical trial using its investigational EV drug, ExoFlo, for the treatment of acute respiratory distress syndrome (ARDS)
- In January 2022, Veru announced that its drug Sabizabulin had received a fast-track designation from the FDA for the treatment of hospitalized COVID-19 patients at high risk of developing acute respiratory distress syndrome (ARDS)
- In January 2021, Fisher & Paykel Healthcare Limited launched its innovative Optiflow+ nasal high-flow therapy system, designed to provide respiratory support for patients suffering from ARDS and other respiratory conditions
